Commentary on “Fish Oil–Containing Lipid Emulsions in Adult Parenteral Nutrition: A Review of the Evidence”

DOI: 10.1002/jpen.1047

Linked content: This article is related to a Review Article by Abbasoglu et al. (https://onlinelibrary.wiley.com/doi/10.1177/0148607117721907) and a Letter to the Editor by Abbasoglu et al. (https://onlinelibrary.wiley.com/doi/10.1002/jpen.1046)

Abbasoglu et al published a narrative review concerning the use of fish oil–containing lipid emulsions in adult parenteral nutrition (PN).1 We wholeheartedly agree with the authors when they state that “high-quality and adequately powered RCTs are necessary” and “well-conducted meta-analyses can be key to demonstrating positive or negative effects.” However, we disagree with other aspects of their review, particularly assertions of a lack of evidence in favor of using fish oil–containing lipid emulsions rather than more traditional lipid formulations.

The authors mentioned that 4 meta-analyses show a significant clinical benefit for fish oil–containing lipid emulsions. There are at least 4 additional meta-analyses that have shown such benefits,2-5 so 8 meta-analyses have results significantly in favor of fish oil in adult PN, but 2 show no significant differences.6,7 Both those showing no significant differences included few trials (6 in each case) and very few (<400) patients.6,7 Moreover, when one was updated with additional studies, it found significantly fewer infectious complications and shorter length of hospital stay in patients given fish oil–containing lipid emulsions.8

Abbasoglu et al stated that “key medical societies are challenged to provide recommendations” for lipid emulsion choice, and that ASPEN does not recommend one lipid emulsion over another. This is disingenuous, as ASPEN states, “When these alternative IVFEs (SMOF [soybean oil, MCT, olive oil, and fish oil emulsion], MCT [medium chain triglycerides], OO [olive oil], and FO [fish oil]) become available in the United States, based on expert opinion, we suggest that their use be considered in the critically ill patient who is an appropriate candidate for PN.”9 Moreover, after assessing the evidence base, the European Society for Parenteral and Enteral Nutrition (ESPEN) recommends fish-oil use in many ICU, surgical, and cancer patients in 2009 and 2017 guidelines.10-14

When making an assessment, the choice of (1) what to include and (2) how to process these data are 2 key variables:15 (1) Abbasoglu et al used broad inclusion criteria (34 studies were included), only excluding studies not in English, of children, or if only enteral nutrition (EN) was used. However, a large number of RCTs were excluded by Abbasoglu et al for reasons that are not clear, but instead they include retrospective/observational studies, which constitute a lower level of evidence. Moreover, many of the studies included “off-label” use of fish oil as the only lipid source. (2) Abbasoglu et al performed a nonsystematic narrative review, considered to be a fairly weak level of evidence within the evidence-based medicine hierarchy, whereas meta-analyses are among the most powerful methods available. Given the weight of evidence from meta-analyses and international guidelines, are the contradictory conclusions from Abbasoglu et al appropriate? Also, the reason given for not doing a meta-analysis was “the low quality of most studies and the substantial heterogeneity,” but they then used data from these same “low-quality” studies to reach their conclusions.

In conclusion, we agree with Abbasoglu et al that further large-scale RCTs are needed, but we disagree that there is little benefit to using fish oil. The weight of evidence, supported by international guidelines, indicates clinical benefits for using fish oil–enriched PN in adult patients.

The ESPEN Expert Group*

*Based upon the ESPEN Workshop “Lipids in the ICU” held in Tel Aviv, Israel, on 23 and 24 November 2014.

This article originally appeared online on January 24, 2018.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Michael Adolph, MD, PhD
Department of Anesthesiology and Intensive Care Medicine, Nutrition Support Team, University Hospital Tuebingen, Germany

Philip C. Calder, BSc (Hons), PhD, DPhil
Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom and National Institute for Health Research Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom

Nicolaas E. Deutz, MD, PhD
Human Clinical Research Facility, Director, Center for Translational Research in Aging & Longevity, Department of Health & Kinesiology, Texas A&M University, College Station, TX, USA

Teodoro Grau Carmona, MD, Ph.D
Hospital Universitario Doce de Octubre, Madrid, Spain

Stanislaw Klek, MD, PhD
Intestinal Failure Center, Stanley Dudrick’s Memorial Hospital, Skawina, Poland

Shaul Lev, MD, PhD
Hasharon ICU, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel and ISCN, Hasharon Hospital, Chairman of ESPEN, Tel Aviv, Israel

Konstantin Mayer, MD, PhD
Department of Internal Medicine, Med. Clinik II, University Hospital of Giessen and Marburg, Giessen, Germany

Adina T. Michael-Titus, Lic Sci., M en Sci., Doct en Sci Centre Lead, Centre for Neuroscience and Trauma, The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Lorenzo Pradelli, MD
AdRes Health Economics and Outcomes Research, Turin, Italy

Mark Puder, MD, PhD
Harvard Medical School, Vascular Biology Program, and the Department of Surgery, Boston Children’s Hospital, Boston, MA, USA

Pierre Singer, MD, PhD
Division of Anesthesiology and Intensive Care of the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel and Head of Department of General Intensive Care and Institute for Nutrition Research, Rabin Medical Center, Hasharon Hospital, Chairman of ESPEN, Tel Aviv, Israel

Hester Vlaardingerbroek, MD, PhD
Department of Pediatrics, Emma Children’s Hospital, Academic Medical Center, Amsterdam, The Netherlands

References

1. Abbasoglu O, Hardy G, Manzanares W, Pontes-Arruda A. Fish oil–containing lipid emulsions in adult parenteral nutrition: a review of the evidence. J Parenter Enteral Nutr. 2019;43:458-470.
2. Palmer AJ, Ho CKM, Ajibola O, Avenell A. The role of omega-3 fatty acid supplemented parenteral nutrition in critical illness in adults: a systematic review and meta-analysis. Crit Care Med. 2013;41:307-316.
3. Chen B, Zhou Y, Yang P, Wan HW, Wu XT. Safety and efficacy of fish oil-enriched parenteral nutrition regimen on postoperative patients undergoing major abdominal surgery: a meta-analysis of randomized controlled trials. J Parenter Enteral Nutr. 2010;34:387-394.
4. Bae HJ, Lee GY, Seong JM, Gwak HS. Outcomes with perioperative fat emulsions containing omega-3 fatty acid: a meta-analysis of randomized controlled trials. Am J Health Syst Pharm. 2017;74:904-918.
5. Kreymann KG, Heyland DK, de Heer G, Elke G. Intravenous fish oil in critically ill and surgical patients—historical remarks and critical appraisal. Clin Nutr. 2017. [Epub ahead of print.]
6. Tian H, Yao X, Zeng R, et al. Safety and efficacy of a new parenteral lipid emulsion (SMOF) for surgical patients: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013;71:815-821.
7. Manzanares W, Dhaliwal R, Jurewitsh B, Stapleton RD, Jeejeebhoy KN, Heyland DK. Parenteral fish oil lipid emulsions in the critically ill: a systematic review and meta-analysis. J Parenter Enteral Nutr. 2014;38:20-28.
8. Manzanares W, Langlois PL, Dhaliwal R, Lemieux M, Heyland DK. Intravenous fish oil lipid emulsions in critically ill patients: an updated systematic review and meta-analysis. Critical Care. 2015;19:167.
9. McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.), J Parenter Enteral Nutr. 2009;33:277-316.
10. Singer P, Berger MM, Van den Berghe G, et al. ESPEN guidelines on parenteral nutrition: Intensive care. Clin Nutr. 2009;28:387-400.
11. Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F. ESPEN guidelines on parenteral nutrition: Surgery. Clin Nutr. 2009;28:378-386.
12. Calder PC, Adolph M, Deutz NE, et al. Lipids in the intensive care unit: recommendations from the ESPEN expert group. Clin Nutr. 2017 [in press].
13. Arends J, Bachmann P, Baracos V, et al. ESPEN guideline: clinical nutrition in surgery. Clin Nutr. 2017;36:623-650.
14. Weimann A, Braga M, Carli F, et al. ESPEN guideline: clinical nutrition in surgery. Clin Nutr. 2017;36:623-650.
15. Khan KS, Kunz R, Kleijnen J, Antes G. Five steps to conducting a systematic review. J R Soc Med. 2003;96:118-121.